Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629858 | 0.89 | AR (1.00) | ARPGR | |
| SCHEMBL4029285 | 0.86 | AR (0.62) | AR | |
| Acetic Acid SCHEMBL7784177 | 0.84 | AR (0.89) | ARPGR | |
| SCHEMBL14620477 | 0.83 | AR (0.61) | AR | |
| SCHEMBL1716347 | 0.83 | AR (0.61) | AR | |
| SCHEMBL1716338 | 0.82 | AR (0.63) | ARPGR | |
| SCHEMBL4031754 | 0.81 | AR (0.79) | ARPGR | |
| SCHEMBL12812542 | 0.81 | AR (0.53) | AR | |
| SCHEMBL4023707 | 0.81 | AR (0.73) | ARPGR | |
| SCHEMBL14218626 | 0.81 | AR (0.60) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE35956-E | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1998-11-10 | — | — | US | claimed |
| US-5627201-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1997-05-06 | — | — | US | claimed |
| EP-0494819-B1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-07-10 | — | — | EP | claimed |
| US-5411981-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1995-05-02 | — | — | US | claimed |
| EP-0494819-A1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-07-15 | — | — | EP | claimed |
| US-11739075-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4122925-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | Medshine Discovery Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-11560371-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20170313662-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS LIMITED (IN) | 2017-11-02 | — | — | US | disclosed |
| WO-2016051423-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS PRIVATE LIMITED (IN) | 2016-04-07 | — | — | WO | disclosed |
| EP-0671156-B1 | Process to prepare cosmetic or pharmaceutical compositions containing liposomes | AVENTIS PHARMA SA (FR) | 2001-10-24 | — | — | EP | disclosed |
| US-6162444-A | Cosmetic or pharmaceutical compositions | HOECHST MARION ROUSSEL (FR) | 2000-12-19 | — | — | US | disclosed |
| US-RE35956-E | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1998-11-10 | — | — | US | disclosed |
| US-5627201-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1997-05-06 | — | — | US | disclosed |
| EP-0494819-B1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-07-10 | — | — | EP | disclosed |
| EP-0671156-A1 | Cosmetic or pharmaceutical compositions containing liposomes | ROUSSEL UCLAF (FR) | 1995-09-13 | — | — | EP | disclosed |
| US-5411981-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1995-05-02 | — | — | US | disclosed |
| EP-0494819-A1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313662-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | KLK4, KLK5, KLK1 | AR 8/4885PGR 2547/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | AR 1545/4885PGR 3724/4885 |
| US-11739075-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CRBN, AR, ESRRA | AR 2/4885PGR 42/4885 |
| US-11560371-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CRBN, AR, SHBG | AR 2/4885PGR 70/4885 |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | AR 1/4885PGR 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.